What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “participants will be treated on Baseline Day 1 with a UC-MSCs product administered subcutaneously. Participants will be observed for 2 to 3 hours after end of study treatment and then followed up for safety assessments over the subsequent 6-month period.”In the company’s words, NCT06737380 on ClinicalTrials.gov
- Tested for
- SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
- Main trialPhase 1
- “The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1. Can UC-MSCs improve kidney function and reduce SLE disease activity? 2. Are UC-MSCs safe and well-tolerated in this patient population? Participants in this study will: * Receive UC-MSCs in a single dose in addition to standard of care treatment. * Provide blood and urine samples for laboratory assessments, including biomarkers and immune profiling (e.g., cytokines, complement proteins, and…”In the company’s words, NCT06737380 on ClinicalTrials.gov
Other drugs for SLE
- RilzabrutinibSanofi · Phase 3
- IMU-838Immunic AG · Phase 3
- TirzepatideEli Lilly · Phase 3
- Descartes-08Cartesian Therapeutics · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2026 | UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026